호흡기 세포 융합 바이러스(RSV) 진단 시장 보고서 : 제품, 최종 용도, 지역별(2025-2033년)

The global respiratory syncytial virus (RSV) diagnostics market size reached USD 1,087.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,152.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.9% during 2025-2033.

Respiratory syncytial virus (RSV) is a viral infection of the lungs and respiratory tract, which can cause asthma, hospitalization, pneumonia, repeated infections, middle ear infection, and death. It can be diagnosed using blood tests, chest x-rays, a swab of secretions, and pulse oximetry by checking for signs like lung inflammation, white blood cell (WBC) count, and oxygen levels in the blood. Some of the commonly available treatment options for RSV are over-the-counter (OTC) medications, intravenous (IV) fluids, humidified oxygen, mechanical ventilation, and inhaled bronchodilators.

Respiratory Syncytial Virus (RSV) Diagnostics Market Trends:

RSV infection can be more serious during the neonatal period as children under two years of age tend to develop severe respiratory symptoms. This, in confluence with the rising focus of parents on child medical care, represents one of the crucial factors fostering the growth of the market. Moreover, the high survival rates after early diagnosis and the easy availability of diagnostic modalities act as other growth-inducing factors. Apart from this, the improving healthcare infrastructure and favorable reimbursement policies for the treatment of hospitalized infants are also contributing to market growth. Furthermore, the advent of advanced techniques like bio- and nanotechnology is facilitating the development of modern detection systems for RSV, such as western blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). Besides this, governing agencies of numerous countries are funding research and development (R&D) projects for the development of new therapeutics. Other factors projected to drive the market are the growing number of clinical vaccine trials, the escalating demand for in-vitro diagnostics, rising incidences of childhood pneumonia and the increasing adoption of molecular diagnostics.

Key Market Segmentation:

Breakup by Product:

• Direct Fluorescent Antibody (DFA) Method
• Rapid Antigen Diagnostic Test (RADTs)
• Molecular Diagnostics
• Chromatographic Immunoassay
• Diagnostic Imaging
• Gel Microdroplets
• Flow Cytometry
• Others

Breakup by End Use:

• Hospitals and Clinics
• Laboratory
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Coris BioConcept, DiaSorin Molecular LLC (DiaSorin Inc), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics Incorporated, Quidel Corporation and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global respiratory syncytial virus (RSV) diagnostics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global respiratory syncytial virus (RSV) diagnostics market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the end use?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global respiratory syncytial virus (RSV) diagnostics market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Respiratory Syncytial Virus (RSV) Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Direct Fluorescent Antibody (DFA) Method
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Rapid Antigen Diagnostic Test (RADTs)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Molecular Diagnostics
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Chromatographic Immunoassay
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Diagnostic Imaging
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Gel Microdroplets
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Flow Cytometry
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Others
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by End Use

• 7.1 Hospitals and Clinics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Laboratory
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Becton, Dickinson and Company
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 bioMerieux SA
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bio-Rad Laboratories Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Coris BioConcept
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 DiaSorin Molecular LLC (DiaSorin Inc)
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 F. Hoffmann-La Roche AG
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 SWOT Analysis
  • 13.3.8 Merck KGaA
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Quest Diagnostics Incorporated
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Quidel Corporation
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Thermo Fisher Scientific Inc.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis